Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
Bausch wins US appeal to block Alvogen generic of diarrhea drug
01:03pm, Thursday, 11'th Apr 2024
A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029.
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgari
Pharma Stock Could Push Back Toward Highs
03:19pm, Wednesday, 10'th Apr 2024
The shares of pharma stock Bausch Health Companies Inc (NYSE:BHC) have taken a tumble since their recent April 3 nearly two-year high of $11.46.
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
02:31pm, Monday, 08'th Apr 2024
Bausch (BHC) initiates litigation against Amneal Pharmaceuticals and its subsidiaries over a generic version of its lead drug Xifaxan.
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
06:15pm, Friday, 05'th Apr 2024
LAVAL, QC / ACCESSWIRE / April 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it filed a lawsuit today
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
10:56am, Wednesday, 03'rd Apr 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
LAVAL, QC / ACCESSWIRE / April 3, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the first public drug plan listings for PrUCERIS® (budes
Salix Pharmaceuticals Releases Fourth Annual Patient Perspectives IBS Impact Report LAVAL, QC / ACCESSWIRE / April 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (
Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?
06:26am, Thursday, 28'th Mar 2024
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
10:56am, Friday, 15'th Mar 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bausch Health Companies to Present at Cowen Annual Health Care Conference
08:00am, Friday, 01'st Mar 2024
LAVAL, QC / ACCESSWIRE / March 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate at the Cowen Annual Health Care Conference
Bausch + Lomb CEO Brent Saunders goes one-on-one with Jim Cramer
03:00pm, Friday, 23'rd Feb 2024
Bausch + Lomb Chairman and CEO Brent Saunders joins 'Mad Money' host Jim Cramer to talk earnings.
Bausch (BHC) Q4 Earnings and Revenues Top Estimates
12:56pm, Friday, 23'rd Feb 2024
Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.
Bausch (BHC) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
10:36am, Thursday, 22'nd Feb 2024
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street
